ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

26,697Medicare Part D Prescriptions Filled, Including Refills

Rank: 4 out of 823

$3.85M Total Retail Price of All Prescriptions

Rank: 1 out of 823

1,232 Patients Receiving at Least One Drug in Part D
77%Patients 65 Years and Older
78% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

28% of this provider’s 1,232 patients filled at least one prescription for a schedule three drug, compared to an average of 18%.

Risky Drugs to Seniors

3% of this provider’s 20,901 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 3%.

Brand Name Drugs

35% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$144 was the average price of a prescription from this provider, compared to $103 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
LEVOTHYROXINE SODIUM 1,162 981 1 6
HYDROCODONE-ACETAMINOPHEN 930 652 S3 2 1
OMEPRAZOLE 877 733 3 5
SIMVASTATIN 651 573 4 2
MELOXICAM 629 538 5 27
GABAPENTIN 585 458 6 8
CARVEDILOL 552 460 7 12
NEXIUM 515 364 8 10
CRESTOR 481 372 9 20
LISINOPRIL 472 385 10 4
LISINOPRIL-HYDROCHLOROTHIAZIDE 455 378 11 39
PREDNISONE 449 348 12 31
TRAMADOL HCL 434 337 13 15
PANTOPRAZOLE SODIUM 314 248 14 30
PRAVASTATIN SODIUM 299 255 15 23
CIPROFLOXACIN HCL 295 240 16 32
PEN NEEDLE 269 178 17 96
METOPROLOL SUCCINATE 269 222 17 9
VOLTAREN 264 220 19 187
CLOPIDOGREL 261 220 20 16
AZITHROMYCIN 260 184 21 48
METOCLOPRAMIDE HCL 259 191 22 95
FUROSEMIDE 241 183 23 7
GLYBURIDE-METFORMIN HCL 238 186 R 24 121
LANTUS SOLOSTAR 237 148 25 129
ATORVASTATIN CALCIUM 231 185 26 13
TORSEMIDE 231 199 26 161
LEVOFLOXACIN 228 174 28 101
CYMBALTA 226 168 29 40
GLIMEPIRIDE 226 185 29 51
POLYETHYLENE GLYCOL 3350 219 178 31 87
CEFUROXIME 216 168 32 237
AMLODIPINE BESYLATE 216 189 32 3
AMLODIPINE BESYLATE-BENAZEPRIL 214 177 34 81
ALENDRONATE SODIUM 207 172 35 42
ZOLPIDEM TARTRATE 207 160 35 17
CYCLOBENZAPRINE HCL 199 102 R 37 63
BYSTOLIC 194 154 38 98
VENTOLIN HFA 192 147 39 242
PLAVIX 175 155 40 25
ALLOPURINOL 175 155 40 61
LYRICA 172 95 42 58
METFORMIN HCL 167 117 43 14
TAMSULOSIN HCL 167 146 43 21
ATELVIA 165 160 45 240
DIOVAN HCT 163 141 46 79
DOXYCYCLINE HYCLATE 161 127 47 110
BENICAR HCT 161 128 47 195
LOVAZA 152 95 49 117
WARFARIN SODIUM 146 140 50 18
LEVEMIR FLEXPEN 143 85 51 221
AMOX TR-POTASSIUM CLAVULANATE 141 97 52 238
ADVAIR DISKUS 139 116 53 68
DICLOFENAC SODIUM 135 100 54 174
SERTRALINE HCL 133 102 55 38
INSULIN SYRINGE 129 105 56 125
LANTUS 127 113 57 76
SINGULAIR 124 91 58 120
METHYLPREDNISOLONE 124 97 58 169
MECLIZINE HCL 122 113 60 184
LOSARTAN-HYDROCHLOROTHIAZIDE 122 112 60 57
CLOTRIMAZOLE 119 92 62 403
HYDRALAZINE HCL 118 97 63 109
DONEPEZIL HCL 115 114 64 24
JANUVIA 115 70 64 70
VYTORIN 114 95 66 234
BENICAR 113 100 67 232
AMITRIPTYLINE HCL 113 73 R 67 89
METHOCARBAMOL 112 65 R 69 136
JANUMET 111 73 70 193
HYDROCODONE BIT-IBUPROFEN 110 72 S3 71 413
SPIRIVA 109 95 72 64
ONGLYZA 109 87 72 275
JALYN 108 89 74 335
SUCRALFATE 107 88 75 154
LOSARTAN POTASSIUM 104 85 76 26
AVODART 103 99 77 167
TRILIPIX 101 82 78 205
NITROFURANTOIN MONO-MACRO 99 80 79 219
CILOSTAZOL 98 79 80 146
ULORIC 97 86 81 422
DIOVAN 97 90 81 35
PAROXETINE HCL 95 89 83 175
TRAZODONE HCL 93 36 84 43
ROPINIROLE HCL 92 78 85 140
COREG CR 91 79 86 379
TRICOR 88 47 87 150
NAMENDA 88 88 87 28
EXFORGE 83 79 89 259
ESCITALOPRAM OXALATE 83 59 89 99
METOPROLOL TARTRATE 83 63 89 11
PROAIR HFA 81 61 92 131
BACLOFEN 78 41 93 90
RANITIDINE HCL 78 52 93 74
MONTELUKAST SODIUM 76 51 95 192
SPIRONOLACTONE 75 42 96 72
CELEBREX 74 64 97 115
FENOFIBRATE 73 49 98 152
NOVOLOG FLEXPEN 72 39 99 256
ACETAMINOPHEN-CODEINE 69 53 S3 100 323
MIRTAZAPINE 67 61 101 82
METOLAZONE 67 60 101 233
SULFAMETHOXAZOLE-TRIMETHOPRIM 67 58 101 91
ISOSORBIDE MONONITRATE ER 67 59 101 49
FLUOXETINE HCL 66 49 105 84
XOPENEX HFA 65 47 106 385
MOMETASONE FUROATE 65 55 106 382
MUPIROCIN 65 60 106 218
EXELON 64 64 109 102
NASONEX 63 51 110 176
ACTONEL 63 63 110 228
LUNESTA 62 46 112 314
AZOR 60 47 113 392
GLIPIZIDE-METFORMIN 59 46 114 371
ACTOS 59 43 114 130
ENABLEX 57 49 116 311
HYDROXYZINE HCL 57 42 R 116 186
ATENOLOL 55 51 118 47
DEXILANT 55 46 118 52
VESICARE 55 43 118 126
GLYCOPYRROLATE 55 42 118 503
SYMBICORT 54 40 122 180
EVISTA 54 54 122 212
HUMALOG 54 34 122 200
AMITIZA 52 37 125 215
PENTOXIFYLLINE 50 43 126 321
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 1, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.